(FILE 'HOME' ENTERED AT 12:42:08 ON 28 NOV 2006)

			•	
	FILE 'CAPLU		' ENTERED AT 12:42:18 ON 28 NOV 2006	
		Ε	EKMAN GUNVOR/IN, AU	
Ll	22	S	E4-5	
		E	ORDEBERG BUNVOR/IN, AU	
L2	1	s	E5	
		E	MALMSTROM ANDERS/IN, AU	
L3	38	s	E2-5	
L4	56	s	L1 OR L2 OR L3	
L5	15312	s	CERVIX	
L6	24212	s	CERVICAL	
L7	30985	s	L5 OR L6	
L8	24	s	L4 AND L7	
L9	15720	s	GLYCOSAMINOGLYCAN	
L10	30924	s	ANTICOAGULANT	
L11	587496	s	SULFAT?	
L12	48428	s	HEPARIN	
L13	8	s	L8 AND (L9 OR L10 OR L11 OR L12)	

```
10/500,284
L13 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:
                          2003:532530 CAPLUS
DOCUMENT NUMBER:
                          139:79188
TITLE:
                           Use of sulfated glycosaminoglycans
                           for establishing effective labor in women
                           Ekman-Ordeberg, Gunvor; Malmstrom, Anders
INVENTOR(S):
PATENT ASSIGNEE(S):
                           Karolinska Innovations AB, Swed.
SOURCE:
                           PCT Int. Appl., 19 pp.
                           CODEN: PIXXD2
DOCUMENT TYPE:
                           Patent
LANGUAGE:
                           English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                          KIND
                                  DATE
                                               APPLICATION NO.
                                               ------
                           ----
                                  -----
     WO 2003055499
                           A1
                                  20030710
                                               WO 2003-SE4
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
              UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
              KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
              FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
              BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                               SE 2002-5
     SE 2002000005
                                  20030703
                           Α
     SE 521676
                           C2
                                  20031125
     CA 2472093
                           AA
                                  20030710
                                               CA 2003-2472093
     AU 2003201787
                           A1
                                  20030715
                                               AU 2003-201787
     EP 1461049
                                  20040929
                                               EP 2003-700633
                           A1
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     NZ 533856
                           Α
                                  20041224
                                               NZ 2003-533856
     CN 1612741
                           Α
                                  20050504
                                               CN 2003-801944
     JP 2005513148
                           T2
                                  20050512
                                               JP 2003-556076
     ZA 2004005015
                                               ZA 2004-5015
                           Α
                                  20050624
```

WO 2003-SE4 W 20030102 The invention discloses the use of sulfated glycosaminoglycans having an anticoagulant activity of 100 BP units/mg or less for the manufacture of a pharmaceutical preparation for prophylactic priming or curative treatment of the cervix and the myometrium for establishing effective labor in women.

US 2004-500284

NO 2004-3190

SE 2002-5

DATE

20030102

20020102

20030102

20030102

20030102

20030102

20030102

20030102

20040624

20040701

20040727

A 20020102

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

A1

Α

ACCESSION NUMBER: 1994:209305 CAPLUS

DOCUMENT NUMBER: 120:209305

US 2005075314

NO 2004003190

PRIORITY APPLN. INFO.:

TITLE: Prostaglandin E2-induced ripening of the human

20050407

20040726

cervix involves changes in proteoglycan

metabolism

Norman, Margareta; Ekman, Gunvor; AUTHOR (S):

Malmstroem, Anders

CORPORATE SOURCE: Dep. Obstetr. Gynecol., Karolinska Inst., Stockholm,

Swed.

SOURCE: Obstetrics & Gynecology (New York, NY, United States)

(1993), 82(6), 1013-20

CODEN: OBGNAS; ISSN: 0029-7844

DOCUMENT TYPE: Journal English

The authors studied how PGE2 induces cervical ripening in women. Cervical biopsies were obtained immediately postpartum from women successfully treated with PGE2 gel intracervically. Six specimens were incubated with [35S] sulfate and five were used to characterize the nonlabeled proteoglycan composition In sep. expts., biopsy specimens from three term pregnant women with unripe cervixes were incubated

with PGE2 in organ cultures. Proteoglycans were isolated and characterized using ion exchange and gel chromatog. and SDS-PAGE. During PGE2-induced cervical ripening, the synthesis of proteoglycans, especially a large chondroitin/dermatan sulfate proteoglycan and biglycan, increased 3-6-fold. This resulted in a net increase in the large proteoglycan in the PGE2-treated cervixes. In organ culture, on the contrary, incubation with PGE2 decreased the proteoglycan synthesis. Thus, PGE2-induced cervical ripening is accomplished by increased remodeling of the cervical connective tissue, involving changed proteoglycan metabolism and composition

L13 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1991:204565 CAPLUS

DOCUMENT NUMBER:

114:204565

TITLE:

Proteoglycan metabolism in the connective tissue of

pregnant and non-pregnant human cervix. An

in vitro study

AUTHOR (S):

Norman, Margareta; Ekman, Gunvor; Ulmsten, Ulf; Barchan, Karin; Malmstroem, Anders

CORPORATE SOURCE:

Karolinska Inst., Danderyd Hosp., Danderyd, S-182 88,

Swed.

SOURCE:

Biochemical Journal (1991), 275(2), 515-20 CODEN: BIJOAK; ISSN: 0306-3275

DOCUMENT TYPE: Journal

LANGUAGE:

English

Profound changes occur in the cervix during pregnancy. In particular, the connective tissue is remodeled. To elucidate the mechanisms behind this process, the metabolism of cervical connective tissue was studied using tissue cultures. Cervical biopsies from nonpregnant and pregnant women were incubated with [35S] sulfate. The proteoglycans of the tissue specimens were purified by ion-exchange and gel chromatog. and characterized by SDS/PAGE and by enzymic degradation In the nonpregnant cervix, the incorporation of [35S] sulfate into the proteoglycans was linear for 48 h. During the 1st 6 h of incubation the accumulation of chiefly 1 small labeled proteoglycan composition of nonsubstituted with dermatan sulfate was recorded. This is in accordance with the known proteoglycan composition of nonpregnant cervical tissue. In addition, small amts. of 2 larger radioactive dermatan/chondroitin sulfate proteoglycans (apparent Mr values 220,000 and > 500,000) were recorded. After longer periods of incubation the proportion of heparan $\underline{{\tt sulfate}}$ proteoglycans increased considerably. The pregnant tissue showed a clearly different composition of labeled proteoglycans. An increased accumulation of the 2 larger dermatan/chondroitin sulfate proteoglycans was seen in addition to the dominant small dermatan sulfate proteoglycan of the nonpregnant cervix. The rate of accumulation of these 2 proteoglycans was .apprx.3-fold higher in the pregnant tissue, whereas that of the small dermatan sulfate proteoglycan was only increased 2-fold. The fact that the concentration of proteoglycans in the pregnant cervix is .apprx.1/2 of that in the nonpregnant cervix indicates that the turnover of proteoglycans in pregnant cervical tissue is significantly increased. The major effect of this profound change of metabolism was a 50% decrease in proteoglycan content and a 2-fold increased proportion of a dermatan sulfate proteoglycan with an apparent Mr of 220,000.

L13 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1985:502461 CAPLUS

DOCUMENT NUMBER:

103:102461

TITLE:

Proteoglycans from cultures of fibroblast from the

human uterine cervix

AUTHOR(S):

Uldbjerg, Niels; Malmstroem, Anders; Ekman,

Gunvor; Ulmsten, Ulf

CORPORATE SOURCE:

Dep. Pharmacol., Univ. Aarhus, Aarhus, Den.

SOURCE:

Gynecologic and Obstetric Investigation (1985), 19(3),

146-54

CODEN: GOBIDS; ISSN: 0378-7346

DOCUMENT TYPE:

Journal

LANGUAGE: English

The synthesis and secretion of proteoglycans by human uterine cervical cells in culture were investigated by incubating the monolayer with 35SO42- and [3H] leucine for 48 h. Two dermatan $\frac{\texttt{sulfate}}{\texttt{were isolated from the medium.}} \ \ \frac{\texttt{sulfate}}{\texttt{cell layer contained the same}}$ proteoglycans, although in different proportions. The major dermatan sulfate proteoglycan, accounting for 55% of the total macromol. 35S, was small, with a mol. weight (MW) of 100,000 daltons. The side chains were calculated to be .apprx.1-3/protein core and included >50% iduronic acid-containing disaccharides. This small dermatan sulfate proteoglycan is very similar to that isolated from the intact human uterine cervix. However, when cells were established in culture, an addnl., larger dermatan sulfate proteoglycan with a MW of 400,000 daltons was synthesized. This proteoglycan contained 4-8 polysaccharide side chains rich in glucuronic acid and 24% of the total macromol. 35S.

L13 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1984:21040 CAPLUS

DOCUMENT NUMBER:

100:21040

TITLE: Ripening of the human uterine cervix related

to changes in collagen, glycosaminoglycans,

and collagenolytic activity

AUTHOR (S): Uldbjerg, Niels; Ekman, Gunvor; Malmstroem,

Anders; Olsson, Kjell; Ulmsten, Ulf

CORPORATE SOURCE: Dep. Physiol. Chem., Univ. Lund, Lund, Swed.

SOURCE: American Journal of Obstetrics and Gynecology (1983),

147(6), 662-6

CODEN: AJOGAH; ISSN: 0002-9378

DOCUMENT TYPE: LANGUAGE:

Journal English

Connective tissue in biopsy specimens taken from the lower part of the uterine cervix in pregnant women at various gestational ages was compared to that in similar specimens from nonpregnant women. The concns. of collagen, sulfated glycosaminoglycans, and hyaluronic acid decreased during pregnancy. At the gestational age of 10 wk, the collagen concentration was 70%, and at term 30%, of that in the nonpregnant cervix. After delivery, no further decrease was observed The extractability of collagen increased during pregnancy, as well as during labor. Also, the water concentration increased. An increase in the collagenolytic activity was observed with advancing gestational age. The collagenase activity and the concentration of leukocyte elastase increased gradually to 10-fold initial values. The physiol. importance of the collagen was also demonstrated, since the cervical dilatation time during spontaneous labor was longer in women with high concns. of

L13 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1984:20837 CAPLUS

DOCUMENT NUMBER:

TITLE: Dermatan sulfate and mucin glycopeptides

from the human uterine cervix

AUTHOR (S): Uldbjerg, Niels; Carlstedt, Ingemar; Ekman,

collagen and shorter in women with low concns. of collagen.

Gunvor; Malmstroem, Anders; Ulmsten, Ulf;

Wingerup, Lars

CORPORATE SOURCE: Dep. Physiol. Chem., Univ. Lund, Lund, S-220 07, Swed. SOURCE:

Gynecologic and Obstetric Investigation (1983), 16(4),

199-209

CODEN: GOBIDS; ISSN: 0378-7346

DOCUMENT TYPE: Journal LANGUAGE: English

High-mol.-weight glycopeptides and glycosaminoglycans were isolated from the human uterine cervix. The major part of the material (82%) was derived from $\overline{\text{cervical}}$ mucins. The remainder contained

hyaluronic acid (3%), heparan sulfate (2%), and dermatan

sulfate (13%). Chondroitin sulfate and keratan

sulfate were not present, but chondroitin sulfate-like

segments were included in the dermatan sulfate. The composition of the cervix apart from the mucus-filled crypts is similar to that

of other fibrous connective tissues.

L13 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1983:571634 CAPLUS

DOCUMENT NUMBER: 99:171634

TITLE: Isolation and characterization of dermatan sulfate proteoglycan from human uterine

AUTHOR (S): Uldbjerg, Niels; Malmstroem, Anders; Ekman,

Gunvor; Sheehan, John; Ulmsten, Ulf; Wingerup,

CORPORATE SOURCE:

Dep. Physiol. Chem., Univ. Lund, Lund, S-220 07, Swed.

SOURCE:

Biochemical Journal (1983), 209(2), 497-503

CODEN: BIJOAK; ISSN: 0306-3275

DOCUMENT TYPE:

Journal

LANGUAGE: English

Proteoglycans extracted from human uterine cervix with 4M guanidinium chloride (I) in the presence of proteinase inhibitors were purified by d.-gradient centrifugation in 4M I/CsCl (starting d. = 1.32 g/mL) followed by DEAE-cellulose and Sepharose chromatog. Only 1 polydisperse proteoglycan was found. The sedimentation coefficient was 2.1 S and the weight-average mol. weight ranged from 73,000 (sedimentation-equilibrium centrifugation) to 100,500 (light-scattering). The core protein was monodisperse, with an apparent mol. weight of 47,000. The proteoglycan contained 30% protein and probably 2 or 3 glycosaminoglycan side-chains/mol. High contents of aspartate, glutamate, and leucine were

present. The glycan moiety of the proteoglycan was exclusively dermatan sulfate, with a copolymeric structure with approx. equal

quantities of iduronic acid- and glucuronic acid-containing disaccharides.

L13 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1983:417232 CAPLUS

DOCUMENT NUMBER:

99:17232

TITLE:

Biochemical changes in human cervical

connective tissue after local application of

prostaglandin E2

AUTHOR (S):

Uldbjerg, Niels; Ekman, Gunvor; Malmstroem,

Anders; Ulmsten, Ulf; Wingerup, Lars

CORPORATE SOURCE:

Malmoe Gen. Hosp., Univ. Lund, Lund, Swed.

SOURCE:

Gynecologic and Obstetric Investigation (1983), 15(5),

291-9

CODEN: GOBIDS; ISSN: 0378-7346

DOCUMENT TYPE:

Journal English

LANGUAGE:

Intracervical administration of PGE2 (I) [363-24-6] in the late 1st trimester of pregnant women induced softening of the cervical

tissue and had marked effects on the collagen and ground substance. I treatment decreased pepsin-extractable collagen levels and collagenase

[9001-12-1] activity, increased sulfated

glycosaminoglycan levels, but did notalter hyaluronic acid

[9004-61-9] or water levels. Apparently, I induces ripening of the

cervix in pregnancy by increasing collagenase activity and

replacing collagen with sulfated glycosaminoglycans.